Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jul;107(5):242-52.
doi: 10.1179/2047773213Y.0000000105.

A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis

Peter Babokhov  1 , Adekunle O Sanyaolu, Wellington A Oyibo, Adetayo F Fagbenro-Beyioku, Nnaemeka C Iriemenam
Affiliations
Review

A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis

Peter Babokhov et al. Pathog Glob Health. 2013 Jul.

Abstract

Despite the recent advances in drug research, finding a safe, effective, and easy to use chemotherapy for human African trypanosomiasis (HAT) remains a challenging task. The four current anti-trypanosomiasis drugs have major disadvantages that limit more widespread use of these drugs in the endemic regions of sub-Saharan Africa. Pentamidine and suramin are limited by their effectiveness against the only first stage of Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, respectively. In addition, melarsoprol and eflornithine (two second stage drugs) each have disadvantages of their own. The former is toxic and has increasing treatment failures while the latter is expensive, laborious to administer, and lacks efficacy against T. b. rhodesiense. Furthermore, melarsoprol's toxicity and decreasing efficacy are glaring problems and phasing out the drug as a frontline treatment against T. b. gambiense is now possible with the emergence of competent, safe combination chemotherapies such as nifurtimox-eflornithine combination treatment (NECT). The future of eflornithine, on the other hand, is more promising. The drug is useful in the context of combination chemotherapy and potential orally administered analogues. Due to the limits of monotherapies, greater emphasis should be placed on the research and development of combination chemotherapies, based on the successful clinical tests with NECT and its current use as a frontline anti-trypanosomiasis treatment. This review discussed the current and future chemotherapy strategies for the treatment of HAT.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, et al. The trypanosomiases. Lancet. 2003;362:1469–80. - PubMed
    1. WHO. WHO/NTD Report update 2011. http://wwwwhoint/neglected_diseases/2010report/WHO_NTD_report_update_20 ..., 1–25 2011
    1. WHO. Neglected Tropical Diseases Booklet 2010. Neglected tropical diseases, hidden successes, emerging opportunities. 2010. http://whqlibdoc.who.int/publications/2009/9789241598705_eng.pdf, 1–71
    1. Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, et al. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr. 2010;9:57. - PMC - PubMed
    1. Simarro PP, Diarra A, Ruiz Postigo JA, Franco JR, Jannin JG. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000–2009: the way forward. PLoS Negl Trop Dis. 2011;5:e1007. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources